Home
>
US Stocks
>
Athenex Inc
Athenex Inc
ATNX

Athenex Inc

$2.7720.86%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
2.9
Today Low/High
2.76 / 2.9
52 Week Low/High
$3.17 / $15.24
P/E ratio
-2.462
Market Cap
$358.53M

Company Details

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company's current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex's employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina.
Organisation
Athenex Inc
Headquaters
Buffalo, New York, US
Employees
599
Industry
Health Technology
CEO
Johnson Lau

Discover more

Frequently Asked Questions

What is Athenex Inc share price today

Can Indians buy Athenex Inc shares?

How can I buy Athenex Inc shares from India?

Can Fractional shares of Athenex Inc be purchased?

What are the documents required to start investing in Athenex Inc stocks?

We are a SEBI registered investement advisor